ID   NK-92MI
AC   CVCL_3755
SY   NK-92 MI; NK-92 mi; NK92-MI; NK92MI; NK-92 transfected with MFG-hIL2
DR   CLO; CLO_0008178
DR   ATCC; CRL-2408
DR   ATCC; PTA-6671
DR   BCRC; 60438
DR   CCLE; NK92MI_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
DR   CCRID; 3111C0002000000065
DR   CCRID; 3131C0001000200022
DR   Cell_Model_Passport; SIDM01201
DR   Cosmic-CLP; 1330981
DR   DepMap; ACH-002289
DR   GDSC; 1330981
DR   GEO; GSM1670278
DR   KCB; KCB 200677YJ
DR   LINCS_LDP; LCL-1127
DR   Wikidata; Q54930658
RX   Patent=US8034332;
RX   PubMed=10365666;
RX   PubMed=27397505;
RX   PubMed=30894373;
WW   http://www.cellresource.cn/fdetail.aspx?id=437
WW   http://www.cellresource.cn/fdetail.aspx?id=480
CC   Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC   Part of: COSMIC cell lines project.
CC   Characteristics: No longer dependent on IL2.
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Transfected with: HGNC; 6001; IL2.
CC   Omics: Deep exome analysis.
CC   Omics: DNA methylation analysis.
CC   Genome ancestry: African=1.91%; Native American=0.5%; East Asian, North=2.04%; East Asian, South=0%; South Asian=0%; European, North=62.71%; European, South=32.85% (PubMed=30894373).
CC   Caution: This cell line is exclusively owned and controlled by NantKwest, Inc. NantKwest and its affiliate, Brink Biologics, Inc. are the sole authorized distributors for both commercial and non-commercial research requestors. There are no other authorized commercial and non-commercial suppliers of NK-92MI. Contact NantKwest and Brink Biologics for information concerning current inventory and cell line use and support.
CC   Discontinued: ATCC; PTA-6671; probable.
CC   Derived from sampling site: Peripheral blood.
ST   Source(s): ATCC; CCRID; Cosmic-CLP
ST   Amelogenin: X,Y
ST   CSF1PO: 11,12
ST   D13S317: 9,12
ST   D16S539: 11,12
ST   D18S51: 12,17
ST   D21S11: 31.2,32
ST   D3S1358: 15
ST   D5S818: 12,13
ST   D7S820: 10,11
ST   D8S1179: 12,15
ST   FGA: 20,22
ST   Penta D: 10,12
ST   Penta E: 12
ST   TH01: 6,9.3
ST   TPOX: 8
ST   vWA: 16,18
DI   NCIt; C82217; Natural killer cell lymphoblastic leukemia/lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens
HI   CVCL_2142 ! NK-92
SX   Male
AG   50Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-07-19; Version: 23
//
RX   Patent=US8034332;
RA   Klingemann H.-G.;
RT   "Interleukin-secreting natural killer cell lines and methods of use.";
RL   Patent number US8034332, 11-Oct-2011.
//
RX   PubMed=10365666; DOI=10.1089/10430349950018030;
RA   Tam Y.K., Maki G., Miyagawa B., Hennemann B., Tonn T.,
RA   Klingemann H.-G.;
RT   "Characterization of genetically altered, interleukin 2-independent
RT   natural killer cell lines suitable for adoptive cellular
RT   immunotherapy.";
RL   Hum. Gene Ther. 10:1359-1373(1999).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M.,
RA   Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M.,
RA   Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A.,
RA   Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//